Head and neck cancer comprises squamous cell carcinomas of the upper aerodigestive tract. There are similarities in their natural history, epidemiology and control. For these cancers premalignant changes can be identified. Smoking and drinking are the major risk factors. The geographical variations in incidence and mortality are indicative of differences in the prevalence of risk factors between countries. The dramatic increase in head and neck cancers is cause for great concern, particularly in Central-Eastern Europe. The great majority of these cancers could be prevented by reducing the prevalence of established risk factors. Screening could be used to detect both precancerous lesions and early invasive cancers; however, no study as yet has demonstrated a reduced incidence and mortality resulting from screening. When setting strategies for prevention, the socioeconomic differentials in incidence and mortality from head and neck cancers need to be taken into account.

No abstract

There is therefore an urgent need to closely monitor performance and to review programme policies and procedures with the aim of increasing both the participation rate and the proportion of women eligible to attend screening.

The organized screening programme managed to increase moderately the coverage of target population. In order to realize the mortality decline due to cervical cancer, participation rate must be increased.

No abstract

Theoretically, there is a real prospect for full eradication of cervical cancer by cytology screening. In several countries the burden of cervical cancer significantly decreased due to regular screening of the population. In Hungary, the complex "gynecological screening", including colposcopic examination, has a long tradition, however, the efforts of several decades are not reflected in the mortality: about 500 women are killed by cervical cancer each year. The screening protocol represents a compromise between the traditional "gynecological screening" and the internationally recommended organized screening: taking sample for cytology is an essential element of the gynecological examination. The National Public Health Programme has established the technical and organizational preconditions of an organized screening programme. The early experiences with the "call-and-recall" organized screening -- started at the end of 2003 -- are unfavourable, because the compliance rates are unacceptably low. The majority of the women receive screening in a traditional way, i.e. outside the programme; another proportion of them simply ignores the invitation, and does not accept the offered screening. To improve the current situation, following the recommendation of "the-state-of-the-art", an attempt is made to intensify the involvement of the primary care personnel. There is a need to revise the current financing system by the political decision-makers in the health field. The access to the screening facilities needs to be improved, the attitude of the medical community changed, and the efficiency of the communication with the public significantly improved.

The CanScreen5 project is a global cancer screening data repository that aims to report the status and performance of breast, cervical and colorectal cancer screening programs using a harmonized set of criteria and indicators. Data collected mainly from the Ministry of Health in each country underwent quality validation and ultimately became publicly available through a Web-based portal. Until September 2022, 84 participating countries reported data for breast (n = 57), cervical (n = 75) or colorectal (n = 51) cancer screening programs in the repository. Substantial heterogeneity was observed regarding program organization and performance. Reported screening coverage ranged from 1.7% (Bangladesh) to 85.5% (England, United Kingdom) for breast cancer, from 2.1% (Côte d’Ivoire) to 86.3% (Sweden) for cervical cancer, and from 0.6% (Hungary) to 64.5% (the Netherlands) for colorectal cancer screening programs. Large variability was observed regarding compliance to further assessment of screening programs and detection rates reported for precancers and cancers. A concern is lack of data to estimate performance indicators across the screening continuum. This underscores the need for programs to incorporate quality assurance protocols supported by robust information systems. Program organization requires improvement in resource-limited settings, where screening is likely to be resource-stratified and tailored to country-specific situations.

A129(anti-VEGF) were estimated based on prices established by Brazilian Drug Market Regulation Chamber. RESULTS: Nine studies were included: eight SR and one HTA. All reviews showed weak strength of recommendation and moderate to high quality of evidence. Sorafenib showed a median progression free-survival time around 6 months and was more effective than placebo, equally effective than interferon, and less effective than sunitinib. Patients who received sorafenib had a higher risk of suffering major adverse events.